The first commercially available immunoassay solution for rapid detection of designer drugs available now
In response to the rise in forensic cases involving synthetic cannabinoids and other designer drugs, Randox Toxicology has released the world's first commercially available immunoassay solution for rapid detection of these drugs in urine and blood.
The Randox Toxicology ELISA offers a highly sensitive screen targeting JWH-018, JWH-073, JWH-398, JWH-200 and a large number of additional metabolites.
Until recently the only method of detection for synthetic cannabinoids was chromatographic analysis.
ELISA offers a fast and effective way of routinely screening for these drugs, eliminating negative samples prior to timely and costly confirmatory procedures.
In addition to the synthetic cannabinoids ELISA, Randox Toxicology plan to release a comprehensive designer drug array for use on their range of Evidence biochip analysers.
The Drugs of Abuse Array V (DoA V) will allow forensic toxicologists to detect eight designer drugs and their metabolites within a single undivided specimen.
The panel targets Methcathinone, Mephedrone, MDPV (also known as bath salts), Benzylpiperazines, Phenylpiperazines, Mescaline, Salvinorin and a number of Synthetic Cannabinoids.
